Foundation Fighting Blindness

Opus Genetics Appoints Brian Leising Vice President, Manufacturing

Retrieved on: 
星期二, 二月 15, 2022
Florida Institute of Technology, Patient, AAV, CEO, Foundation, Science, Licensure, IND, Toxicology, Manufacturing, Biology, Florida Institute for Human and Machine Cognition, Biotechnology, Novartis Gene Therapies, Severe cognitive impairment, Genetics, Retina, Visual impairment, University, History of the University of Maryland, College Park, GLOBE, Foundation Fighting Blindness, Pharmaceutical industry, Opus

RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced the appointment of Brian Leising as Vice President of Manufacturing.

Key Points: 
  • RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced the appointment of Brian Leising as Vice President of Manufacturing.
  • Prior to Novartis Gene Therapies, Mr. Leising was Director of Clinical Gene Therapy Manufacturing at Pfizers former Bamboo facility overseeing Phase 1 manufacturing of their AAV-based gene therapies and future clinical manufacturing infrastructure.
  • Opus has an incredible opportunity to move strong and validated science and well-characterized material into the clinic expeditiously, said Mr. Leising.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.

Diana Davis Spencer Foundation Pledges $5M to Foundation Fighting Blindness for Inherited Retinal Disease Research

Retrieved on: 
星期四, 一月 27, 2022
Drug discovery, Retinitis pigmentosa, Education, Program, Quality of life, Entrepreneurship, Retina, Acceleration, Macular degeneration, Visual impairment, Research, Freedom, Foundation Fighting Blindness, Usher syndrome, Investor, Doctor of Philosophy, Environment, MD, MD–PhD, CEO, Foundation, Pharmaceutical industry

"We are honored by the Diana Davis Spencer Foundation's relentless commitment to supporting the mission of the Foundation Fighting Blindness to find treatments and cures for inherited retinal diseases," said Benjamin Yerxa, PhD, chief executive officer, Foundation Fighting Blindness.

Key Points: 
  • "We are honored by the Diana Davis Spencer Foundation's relentless commitment to supporting the mission of the Foundation Fighting Blindness to find treatments and cures for inherited retinal diseases," said Benjamin Yerxa, PhD, chief executive officer, Foundation Fighting Blindness.
  • In addition, the Foundation Fighting Blindness will develop the Diana Davis Spencer Foundation Career Development Award to provide financial support and protected time to conduct clinical research to individuals with MD or MD/PhD degrees.
  • "We're thrilled to continue our longstanding support for the Foundation Fighting Blindness," said Abby Moffat, president and CEO of the Diana Davis Spencer Foundation.
  • Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research.

Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer

Retrieved on: 
星期三, 一月 19, 2022
Research, Patient, Behavioural Insights Team, Foundation Fighting Blindness, Visual impairment, Science, Foundation, Severe cognitive impairment, Retinitis pigmentosa, Genetics, Culture, Marketing, Heart, Macular degeneration, Doctor of Philosophy, Retina, AAV, Usher syndrome, Pharmaceutical industry, Management, Opus

COLUMBIA,Md., Jan. 19, 2022 /PRNewswire/ --The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, announced today the promotion of Jason Menzo to president and chief operating officer, effective immediately.

Key Points: 
  • COLUMBIA,Md., Jan. 19, 2022 /PRNewswire/ --The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, announced today the promotion of Jason Menzo to president and chief operating officer, effective immediately.
  • "We are excited to have Jason as president, along with continuing his current operational responsibilities," said David Brint, chair of the Foundation Fighting Blindness board of directors.
  • Foundation chief executive officer, Benjamin Yerxa, PhD said, "Jason's impact on the Foundation has been undeniable.
  • "I am proud of the advances we have made to date and remain focused on new ways we can accelerate future milestones," said Jason Menzo, president and chief operating officer.

Doheny Eye Institute Announces the Appointment of Deborah Ferrington, PhD as Chief Scientific Officer

Retrieved on: 
星期四, 一月 13, 2022
Illustration, Research, Patient, BrightFocus Foundation, Biology, NIH, CSO, National Eye Institute, University, Eye, Minneapolis–Saint Paul, AMD, Science, Visual impairment, Foundation Fighting Blindness, Doheny Eye Institute, National Institute on Aging, CEO, Department, Foundation, Severe cognitive impairment, Health, National Institute, Development, Permanent, National, NIA, Education, NEI, Doctor of Philosophy, Glaucoma, Professor, Institute, Drainage, Management, Pharmaceutical industry, Ophthalmology, Biochemistry

LOS ANGELES, Jan. 12, 2022 /PRNewswire/ -- Doheny Eye Institute, a global leader in vision research and basic science to save human eyesight, has announced that Deborah Ferrington, PhD, is joining the organization as Chief Scientific Officer (CSO).

Key Points: 
  • LOS ANGELES, Jan. 12, 2022 /PRNewswire/ -- Doheny Eye Institute, a global leader in vision research and basic science to save human eyesight, has announced that Deborah Ferrington, PhD, is joining the organization as Chief Scientific Officer (CSO).
  • "We are thrilled to have Deb join the Doheny team," said Marissa Goldberg, CEO of Doheny Eye Institute.
  • "I've been impressed with the entire Doheny Eye Institute team, and its affiliation partner, UCLA Stein Eye Institute," Dr. Ferrington continued.
  • Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best in patient care, vision research, and education.

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine

Retrieved on: 
星期三, 一月 5, 2022
EDIT, Therapy, Lists of diseases, Gene editing, Technology, Enzyme, Research, Venture round, Patient, Cystic Fibrosis Foundation, Forward-looking statement, DNA, Series, Gene Codes Corporation, CEO, Foundation, CIO, Gene, Foundation Fighting Blindness, Coding, Automation, Genome, Cystic fibrosis, GLOBE, Visual impairment, D1 Capital Partners, Biotechnology, Symbiosis, Pharmaceutical industry, Risk management, Vaccine, Director

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing Gene Coding, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing Gene Coding, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.
  • As part of the Series B financing, Craig Gordon, M.D., Founder, CEO and CIO of GordonMD Global Investments, has joined the Companys Board of Directors.
  • SalioGens Gene Coding platform is designed to turn on, turn off or modify the function of any gene in the genome.
  • SalioGen Therapeutics has launched Gene Coding, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration Technology (EDIT) platform.

The Blind Boys of Alabama Team up with the Foundation Fighting Blindness and Two Blind Brothers for Music to our Eyes Livestream Music Series

Retrieved on: 
星期四, 十二月 16, 2021
List of lifetime achievement awards, Hole, Severe cognitive impairment, My Blind Brother, Foundation Fighting Blindness, Lifetime, Music, Macular degeneration, Grammy Awards, Amazing Grace, Mavis Staples, The Blind Boys of Alabama, Research, Visual impairment, Retinitis pigmentosa, Usher syndrome, COO, NPR, Facebook, Partnership, Gospel Music Hall of Fame, Foundation, Retina, Pharmaceutical industry, Entertainment

In partnership with Two Blind Brothers, this Facebook series will feature the Blind Boys of Alabama on Thursday, December 16, 2021, at 8 p.m.

Key Points: 
  • In partnership with Two Blind Brothers, this Facebook series will feature the Blind Boys of Alabama on Thursday, December 16, 2021, at 8 p.m.
  • The Blind Boys of Alabama are recognized worldwide as living legends of gospel music.
  • "It was great to be in-person with the Blind Boys of Alabama for the first time in our Music to Our Eyes series," says Jason Menzo, COO at the Foundation.
  • "The Blind Boys are legendary, and each member is a unique inspiration for those in the vision loss community."

Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseases

Retrieved on: 
星期三, 十二月 15, 2021
Organization, Retina, Publishing, PRPH2, Macular dystrophy, Education, UC San Diego Health, Doctor of Philosophy, Foundation Fighting Blindness, Visual impairment, Program, Awareness, Population, Macular degeneration, University of California, San Diego, Research, Welfare, Severe cognitive impairment, Retinitis pigmentosa, RDS, Usher syndrome, University, Foundation, Pharmaceutical industry

COLUMBIA, Md., Dec. 15, 2021 /PRNewswire/ --The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation.

Key Points: 
  • COLUMBIA, Md., Dec. 15, 2021 /PRNewswire/ --The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation.
  • In addition, the Foundation Fighting Blindness will partner with the University of California San Diego to conduct a workshop under the title of "Nixon Visions Foundation Inherited Macular Dystrophy Comprehensive International Workshop with Special Focus on PRPH2."
  • Their support of the Foundation's mission to find treatments and cures for inherited retinal diseases is inspiring," said Benjamin Yerxa, PhD, chief executive officer, Foundation Fighting Blindness.
  • In coordination with the Nixon Visions Foundation, the Foundation Fighting Blindness will build awareness in the inherited retinal disease community about PRPH2 (also known as RDS, which encodes the peripherin-2 protein) mutations and its effect on blindness.

Contemporary Productions Announces New Partnerships with Entertainment Industry Veterans Joe Litvag and Paula Balzer

Retrieved on: 
星期四, 十一月 18, 2021
Sale, Wells Fargo, Industry, Balzer, Clear, Blackbird, Partnership, Live Nation (events promoter), International Tennis Hall of Fame, AEG, LiveStyle, Marketing, Culture, Live Nation Entertainment, Efficiency, Foundation Fighting Blindness, Professional Golfers Association, CMI, Contemporary history, Kraft Foods, World Wide Technology, CMO, Management

ST. LOUIS, Nov. 18, 2021 /PRNewswire/ -- St. Louis-based Contemporary Productions announced today its further expansion into specialized areas of the live entertainment industry to fuel growth.

Key Points: 
  • ST. LOUIS, Nov. 18, 2021 /PRNewswire/ -- St. Louis-based Contemporary Productions announced today its further expansion into specialized areas of the live entertainment industry to fuel growth.
  • The expansion also includes the engagement of senior marketing executive Paula Balzer, an architect of modern-day live entertainment and brand marketing.
  • "Thepartnerships with Paula andJoeincrease ourservice offerings andallows us to be more agile and innovative," saysSteveSchankman, President of Contemporary Productions.
  • Balzer ran Contemporary Productions marketing division, CMI, prior to its sale to SFX Entertainment.

Opus Genetics Announces Presence at Eyecelerator@AAO 2021

Retrieved on: 
星期一, 十一月 8, 2021
Society, American Academy of Ophthalmology, Industry, Science, CEO, AAO, Severe cognitive impairment, Partnership, Foundation, American Academy, Cataract, Annual general meeting, GLOBE, American Society of Cataract and Refractive Surgery, Refractive surgery, Foundation Fighting Blindness, ASCRS, Patient, AAV, Genetics, Visual impairment, Pharmaceutical industry

RALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that Ben Yerxa, Ph.D., acting CEO of Opus and CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, will deliver a company presentation at Eyecelerator@AAO 2021, on Thursday, November 11, 2021, in New Orleans.

Key Points: 
  • RALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that Ben Yerxa, Ph.D., acting CEO of Opus and CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, will deliver a company presentation at Eyecelerator@AAO 2021, on Thursday, November 11, 2021, in New Orleans.
  • Were thrilled to be invited to introduce Opus and highlight our innovative model at Eyecelerator, said Dr. Yerxa.
  • Eyecelerator@AAO 2021 is ophthalmologys next-generation business conference that brings together leading ophthalmic companies and important new startups for fresh perspectives.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.

RD Fund Announces Fundraising Efforts Underway for RD Fund 2

Retrieved on: 
星期四, 十月 28, 2021
Opus, IRD, Visual impairment, Research, Gordon Gund, MBA, Foundation, Novartis, Investment, RD, CEO, Macular degeneration, Foundation Fighting Blindness, Therapy, Usher syndrome, Doctor of Philosophy, Retina, Fund, Severe cognitive impairment, Pharmaceutical industry

RALEIGH, N.C., Oct. 28, 2021 /PRNewswire/ --Today, the RD Fund (Retinal Degeneration Fund) the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research toward preventions, treatments and cures for the entire spectrum of retinal degenerative diseases announces fundraising efforts are underway for RD Fund 2, targeting at least $75 million in new capital via major philanthropic donations.

Key Points: 
  • RALEIGH, N.C., Oct. 28, 2021 /PRNewswire/ --Today, the RD Fund (Retinal Degeneration Fund) the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research toward preventions, treatments and cures for the entire spectrum of retinal degenerative diseases announces fundraising efforts are underway for RD Fund 2, targeting at least $75 million in new capital via major philanthropic donations.
  • RD Fund 2 has the ability to lead investments and the flexibility to make follow-on investments in RD Fund 1 companies.
  • The primary focus of the Fund is to invest in therapeutics; however, RD Fund 2 has the ability to make investments in services and technologies that help advance the mission.
  • To date, RD Fund 2 has raised over $40 millionin committed capital, which includes anchor commitments made by Paul Manningand Gordon Gund.